Mirvetuximab Soravtansine
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mirvetuximab Soravtansine |
| DrugBank ID | DB12489 |
| Brand Names (EU) | Elahere |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 97.95% |
Approved Indication (EMA)
Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | antithrombin deficiency type 2 | 97.95% | DL |
| 2 | heparin cofactor 2 deficiency | 97.83% | DL |
| 3 | factor 5 excess with spontaneous thrombosis | 97.81% | DL |
| 4 | candidiasis | 97.69% | DL |
| 5 | plasma cell myeloma | 97.61% | DL |
| 6 | indolent plasma cell myeloma | 97.41% | DL |
| 7 | tinea corporis | 96.84% | DL |
| 8 | thrombophilia | 96.70% | DL |
| 9 | uterine polyp | 96.56% | DL |
| 10 | pediatric systemic lupus erythematosus | 96.55% | DL |
| 11 | polyp of vocal cord | 96.49% | DL |
| 12 | polyp of middle ear | 96.48% | DL |
| 13 | polyp of frontal sinus | 96.44% | DL |
| 14 | polyp of external auditory canal | 96.43% | DL |
| 15 | polyp of ureter | 96.42% | DL |
| 16 | polyp of vulva | 96.41% | DL |
| 17 | fibroepithelial polyp | 96.38% | DL |
| 18 | neoplastic polyp | 96.33% | DL |
| 19 | epulis | 96.33% | DL |
| 20 | mantle cell lymphoma | 96.14% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.